Grb2 monomer-dimer equilibrium determines normal versus oncogenic function by Ahmed, Z et al.
ARTICLE
Received 25 Jan 2015 | Accepted 29 Apr 2015 | Published 24 Jun 2015
Grb2 monomer–dimer equilibrium determines
normal versus oncogenic function
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The adaptor protein growth factor receptor-bound protein 2 (Grb2) is ubiquitously expressed
in eukaryotic cells and involved in a multitude of intracellular protein interactions. Grb2 plays
a pivotal role in tyrosine kinase-mediated signal transduction including linking receptor
tyrosine kinases to the Ras/mitogen-activated protein (MAP) kinase pathway, which is
implicated in oncogenic outcome. Grb2 exists in a constitutive equilibrium between
monomeric and dimeric states. Here we show that only monomeric Grb2 is capable of
binding to SOS and upregulating MAP kinase signalling and that the dimeric state is
inhibitory to this process. Phosphorylation of tyrosine 160 (Y160) on Grb2, or binding of a
tyrosylphosphate-containing ligand to the SH2 domain of Grb2, results in dimer dissociation.
Phosphorylation of Y160 on Grb2 is readily detectable in the malignant forms
of human prostate, colon and breast cancers. The self-association/dissociation of Grb2
represents a switch that regulates MAP kinase activity and hence controls cancer
progression.
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G
rowth factor receptor-bound protein 2 (Grb2) is an
adaptor protein with no intrinsic enzymatic activity which
is ubiquitously expressed in all eukaryotic cells. It was
originally discovered as epidermal growth factor receptor (EGFR)
interacting protein1 but is now known to form complexes with a
wide variety of cellular proteins including, but not limited to,
protein tyrosine kinases, receptor tyrosine kinases, phosphatases,
adaptors and intracellular scaffolds2–7. Grb2 has a modular
architecture consisting of a central Src homology 2 (SH2) domain
ﬂanked by two Src homology 3 (SH3) domains. The N-terminal
SH3 (N-SH3) has been reported to be constitutively associated
with the mammalian homologue of the drosophila protein
son-of-sevenless (SOS), a guanine nucleotide exchange factor
(GEF) that acts on the Ras subfamily of small GTPases8.
Under non-stimulatory conditions the Grb2–SOS complex
resides in the cytoplasm. However, following receptor activation
phosphorylated receptor tyrosine kinases (RTKs) and RTK-
docking proteins such as Shc, IRS1-4 and FRS2/3 serve as
recognition sites for the Grb2-SH2 domain6,9. As a result SOS is
recruited to the plasma membrane leading to the activation of
mitogen-activated protein kinase (MAPK) signalling cascade10,11.
Mechanisms through which control of signal transduction is
exerted are vital in the regulation of cell response and function
as well as in disease. With this in mind, two important features
of Grb2 function have been reported, but their functional
roles have not been fully elucidated: (1) Grb2 exhibits a
monomer–dimer equilibrium12–14 and (2) tyrosine residues on
Grb2 can be phosphorylated (for example by CD3 and CD4
(ref. 15), prolactin16 and vascular endothelial growth factor17).
Furthermore, Grb2 is speciﬁcally phosphorylated on tyrosine
residue 160 (Y160) by c-Src18, BCR-Abl19, ﬁbroblast growth
factor receptor 2 (FGFR2)20, NPM-ALK, TPR-Met and
TEL-JAK2 (ref. 21).
Here we resolve these elusive roles by demonstrating that Grb2
is only functional in MAPK signal transduction when it is in its
monomeric form; and that dissociation of the constitutive dimer
is facilitated by either phosphorylation of Y160 (pY160) or
through the binding of a tyrosylphosphate-containing ligand.
Therefore, rather than being a passive adaptor, Grb2 functions as
a key control point in MAPK signalling. Our data also reveal the
presence of high levels of pY160, the monomeric signalling active
form of Grb2, in cancer tissue cells and suggest that this could
be a marker for proliferative MAPK activation and resulting
oncogenic outcome.
Results
Grb2 dimer is perturbed by phosphorylation of Y160. We
sought to identify the factors regulating Grb2 monomer/dimer
equilibrium which might deﬁne a switching mechanism for
Grb2-mediated signal transduction. Since Y160 lies within the
previously reported dimer interface and forms a hydrogen
bond with E87 on the partner protomer13 (Fig. 1a), tyrosine
kinase post-translational modiﬁcation of Y160 could perturb
dimerization through a repulsive charge or steric clash effect.
We generated a phosphorylation charge mimetic Grb2 mutant
Y160E, designed such that the charge on the mutated glutamic
acid residue repels the proximal E87 in the partner protomer and
hence abrogates dimer formation (Fig. 1a). We also produced a
mutant whereby two asparagine residues in the Grb2 dimer
interface at positions 188 and 214 were mutated to aspartic acids
(N188/214D). This mutant was unable to dimerize due to the
juxtaposition of the two substituted negatively charged groups
(Fig.1a). The N188/214D mutant provides a phosphorylation-
independent dimerization-defective control protein to assess
the physiological relevance of Y160 phosphorylation. The
wild-type Grb2 (WTGrb2), Y160E (Y160EGrb2) and N188/214D
(N188/214DGrb2) mutants were expressed and puriﬁed from
bacteria. To conﬁrm their stability we performed binding studies
with known ligands (Supplementary Fig. 1). The monomer–
dimer equilibrium was measured by microscale thermophoresis
(MST) after N-terminal labelling with Ato488. WTGrb2 has an
apparent dimerization constant (Kd) of B0.7 mM (Fig.1b)
consistent with the previously reported value12. The Y160EGrb2
and N188/214DGrb2 on the other hand showed no monomer–
dimer transitions (Fig. 1c,d). In order to conﬁrm the monomeric
status of the two mutants we performed additional experiments
using dynamic light scattering, analytical gel ﬁltration,
ﬂuorescence anisotropy and time-resolved ﬂuorescence aniso-
tropy, native polyacrylamide gel electrophoresis (Supplementary
Fig. 2). Under all conditions WTGrb2 formed a concentration-
dependent dimer whereas the two mutants were incapable of
dimer formation.
Dimerization of WTGrb2, Y160EGrb2 and N188/214DGrb2 was
assessed in cells using ﬂuorescence lifetime imaging microscopy
(FLIM) to measure ﬂuorescence resonance energy transfer
(FRET) between two Grb2 protomers. Cyan ﬂuorescence
protein (CFP)-tagged Grb2 (CFP–Grb2) and red ﬂuorescence
protein (RFP)-tagged Grb2 (RFP–Grb2) were co-transfected into
mammalian cells. Grb2 dimerization can only be seen in cells
expressing the wild-type Grb2 (CFP–WTGrb2/RFP–WTGrb2)
(Fig. 1e and Supplementary Fig. 3). Cells expressing Y160EGrb2
and N188/214DGrb2 show no evidence of dimerization.
To demonstrate that phosphorylation of the wild-type
Grb2 disrupts dimerization, we devised a pseudo single molecule
FLIM (smFLIM) experiment. Bacterially expressed and puriﬁed
His-tagged WTGrb2 was N-terminally labelled with Atto488 and
immobilized on Talon beads, while non-tagged WTGrb2 was
labelled with Atto550. After measurement of the reference
lifetime of Atto488–WTGrb2, Atto550–WTGrb2 was added and
allowed to form a complex. The ﬂuorescence lifetime population
showed a distinct left shift to a shorter value indicating that FRET
has occurred (Fig. 2). Incubation for one hour in the presence of
puriﬁed FGFR2 cytoplasmic domain alone had no effect on the
FRET lifetime between the Grb2 protomers. However a further
hour of incubation in the presence of ATP and MgCl2 in order to
phosphorylate Y160 on Grb2 (ref. 20) resulted in a shift of the
average ﬂuorescence lifetime towards the original reference
lifetime for Atto488–WTGrb2 alone (Fig. 2), demonstrating
that the formation of the Grb2 dimer was abrogated by
phosphorylation. These ﬁndings clearly demonstrate that the
disruption of Atto488–Grb2/Atto550–Grb2 complex is FGFR2
activation dependent.
Tyrosylphosphorylated ligand results in dimer dissociation.
From the reported crystal structure13 Y160 appears to form a
hydrogen bond with E87 of the partner protomer (Fig. 1a). Since
E87 lies within the conserved FLI/VRE motif of the SH2 domain
(which is involved in recognition of phosphorylated tyrosine
residues), the insertion of a tyrosylphosphate into the binding
pocket on the SH2 domain might be expected to perturb the side
chain position of E87 and disrupt the interaction between Y160
and E87. Using the previously described smFLIM method we
determined that the addition of a tyrosylphosphopeptide based
on the sequence of the known Grb2 ligand Shc (pShc) leads to
dissociation of Grb2 dimers into the monomeric form (mGrb2)
(Fig. 3). The addition of a proline-rich peptide derived from SOS
which binds to the SH3 domains of Grb2 had no effect on
dimerization on the surface of the Talon beads (Supplementary
Fig. 4a). We conﬁrmed this observation by measuring the
monomer–dimer equilibrium of Grb2 using MST. Since Grb2 is
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monomeric, in the presence of a saturating concentration of
pShc no apparent change in the oligomeric state of the protein
was observed (Supplementary Fig. 4b). As expected similar
experiments in the presence of the SOS1 peptide, Grb2 undergoes
a dimer-to-monomer dissociation which has an identical
apparent Kd (B0.7 mM) to wild-type protein in the absence of
peptide binding (Supplementary Fig. 4c). These results are
consistent with previously reported NMR data where Grb2
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Figure 1 | In vitro and in vivo WTGrb2 form dimers. (a) Homodimer with individual Grb2 protomers of the dimer depicted using surface (green) and ribbon
(blue/purple) representations (derived from PDB 1GRI). Individual SH2 and SH3 domains of the protomers are differentially coloured and labelled. Zoomed
box (top)—Y160 of one protomer (purple) is buried in the dimer interface, packing against the CSH3 domain and hydrogen bonding with E87 of the other
protomer chain (green). Zoomed box (bottom)—hydrogen bonded Asn188 (green) and Asn214 (purple) in the dimer interface. (b) Grb2 dimerization
measured by MST. Unlabelled WTGrb2 protein (7.3 nM to 30 mM) was titrated into a ﬁxed concentration of labelled Grb2 (100 nM). The data for
thermophoresis was recorded at 20 C using the blue LED at 20% and IR-Laser at 40%. The isotherm derived from the raw data and ﬁtted according to the
law of mass action to yield an apparent Kd dimer of 0.76±0.20mM. (c) The data points representing the MST results of the Y160E mutant, which show a
scattered distribution and unsuitable for ﬁtting. (d) The thermophoresis results of the N188/214D mutant, as with Y160E the data is unsuitable for ﬁtting
analysis. (e) FLIM of Grb2 dimerization in mammalian cells through FRET measurements. CFP- and RFP-tagged wild-type or the Grb2 mutants together
with controls were co-transfected in HEK293T cells as indicated on the ﬁgure. The results show a clear shortening of the average lifetime distribution for
ﬂuorophore in cells expressing the WTGrb2. This is due to FRET between the CFP–Grb2 and RFP–Grb2. The Y160E and N188/214D mutants on the other
hand show an average lifetime distribution comparable to the controls indicating no FRET. Scale bar, 25mm.
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was found to be monomeric in the presence of a
phosphopeptide22.
Monomeric Grb2 is the signalling active form. We have
shown two independent mechanisms of Grb2 dissociation, both
dependent on tyrosine kinase activity. Both these mechanisms
could play a fundamental role in Grb2-mediated intracellular
signalling. Since Grb2 is known to bind to its downstream effector
SOS1, we postulate that only mGrb2 elicits downstream effector
function and hence the dimeric Grb2 (dGrb2) is incapable of
signal transduction. We tested this hypothesis by investigating
the downstream signalling effects of mGrb2 versus dGrb2 in
mammalian cells. In cells overexpressing high concentrations
the population of Grb2 is expected to be predominantly
dGrb2, whilst the dimerization-defective Grb2 mutants will be
monomeric regardless of their intracellular concentrations. Cells
were transfected with WTGrb2 and Y160EGrb2, and downstream
MAPK signalling was compared. The results show that
overexpression of WTGrb2 leads to a signiﬁcant decrease in
FGF2- and EGF-induced extracellular signal-regulated kinases
(ERK) phosphorylation. An equivalent level of dimerization-
defective mutant overexpression on the other hand retains ligand-
induced ERK activity (Fig. 4a and Supplementary Fig. 5a).
We also conﬁrmed Grb2 concentration-dependent MAPK
inhibition by serially increasing in the intracellular Grb2 protein
concentration in cells. A direct correlation between increased
Grb2 concentration and decreased MAPK was observed
(Supplementary Fig. 5c–e). Since the formation of the Grb2–SOS
complex is pivotal for RTK-stimulated Ras/MAP kinase
activation, we investigated whether the differential complex for-
mation by dGrb2 versus mGrb2 with SOS1 could explain the
observed suppression of ERK phosphorylation. Grb2 was afﬁnity
puriﬁed from cells and the resulting co-precipitating complex
was analysed for SOS1 (Fig. 4b and Supplementary Fig. 5b). The
results show that the monomeric Y160EGrb2 and N188/214DGrb2
form stable complexes with SOS1 whereas the dimeric WTGrb2
does not. As a control the immunoblot was re-probed with anti-
FRS2 antibody, which showed that both dGrb2 and mGrb2 were
equally proﬁcient in precipitating the upstream adaptor protein
required for FGF receptor signalling.
The direct interaction of either dGrb2 or mGrb2 with SOS1 in
cells was tested using FLIM. RFP-tagged WTGrb2 and Y160EGrb2
were co-transfected with GFP-tagged SOS1 (GFP–SOS1). The
results show that the monomeric Grb2 mutants form more stable
interactions with SOS1 than WTGrb2 (Supplementary Fig. 6).
Together these results conﬁrm that a monomeric Grb2 is
necessary and sufﬁcient to form the interaction with SOS1 and
propagate the MAPK signalling pathway.
Monomeric Grb2 is associated with malignant cancers. Y160 is
a target phosphorylation site for many receptor and non-receptor
tyrosine kinases that are involved in cancer growth and
metastasis21. This suggests dGrb2 may have an inhibitory role
whilst mGrb2 promotes proliferative downstream signalling.
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Figure 2 | Grb2 tyrosine phosphorylation disrupts dimerization. FRET between Atto488–Grb2 and Atto550–Grb2 measured with FLIM. The panels
on the right show the distribution of the average ﬂuorescence lifetime. The middle image is the representation of the measured lifetime as a false
colour map. On the right hand side are zoomed images of a bead with a characteristic imperfection. The mean lifetime of Atto488–Grb2 is centred at
B1.9 ns. The addition of the acceptor Atto550–Grb2 leads to an apparent left shift in the average lifetime. This is clear from the appearance of a new
peak at B1.6 ns as a result of FRET between Atto488–Grb2 and Atto550–Grb2. Addition of FGFR2 has no effect on the apparent average lifetime.
However, further addition of ATP/MgCl2 reversed the average lifetime to 1.9 ns providing evidence for the disruption of FRET and hence the disruption
of dimerization on phosphorylation of Grb2. Scale bars, 50mm.
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Here we have shown that Y160 phosphorylation-dependent
dissociation of dGrb2 is sufﬁcient to induce upregulation of
MAPK signalling (Fig. 4) which is associated with proliferation
and metastasis23–25. Therefore, we would predict that in tyrosine
kinase-driven cancers phosphorylation of Y160 and the resulting
dissociation of Grb2 dimers would be capable of inducing cell
proliferative and metastatic outcome. This would suggest that
pY160 could be used as marker for elevated tyrosine kinase-
mediated ERK signalling in human cancers. We therefore
generated a site-speciﬁc anti-pY160 antibody against pY160.
This antibody was tested exhaustively and found to be suitable for
detecting Y160-phosphorylated Grb2 in western blotting and in
immunohistochemistry (IHC) analysis (Supplementary Fig. 7).
We performed IHC analysis of a multi-tumour tissue array
containing 40 human tumour samples from 27 different organs.
The results show that Y160 was highly phosphorylated in a
signiﬁcant number of high-grade malignant tumours but not in
the lower grade or non-malignant counterpart tumours or in
corresponding normal tissue (Supplementary Fig. 8). Y160
phosphorylation was particularly prevalent in higher grade,
late-stage malignant tumours of the colon and prostate
(Fig. 5a–d). Therefore, we performed additional IHC analysis
on 118 colon and 42 prostate cancer tissues with the anti-pY160
antibody, which shows a clear correlation between disease
progression and Grb2 phosphorylation (Fig. 5e,f). Higher
levels of Y160 phosphorylation were again clearly associated
with higher-grade malignant tumours. In addition we performed
protein microarray analysis on 55 human breast tumours with
matched normal tissue using the pY160 antibody. The results
revealed Y160 phosphorylation was absent in normal breast
samples, however 12 out of 55 breast tumour samples were
positive for pY160 (Supplementary Fig. 9a–c). To conﬁrm the
results of the protein microarray, we selected two positive breast
tumour samples and the corresponding normal matched sample
for western blotting analysis. The results show elevated Grb2
expression and phosphorylation, MAP kinase and tyrosine kinase
activity in the tumour samples compared with the normal cohort.
Furthermore, it was possible to assign the elevated pY160 level of
one patient to increased EGFR expression and kinase activity
(Supplementary Fig. 9d).
Discussion
The discovery of the adaptor protein Grb2 as receptor tyrosine
kinase-interacting protein 20 years ago was a key point in
deﬁning RTK signal transduction26,27. Since then a plethora of
Grb2-interacting proteins have been reported (http://string-
db.org). The interaction between Grb2 and SOS and the
recruitment of the Grb2–SOS complex to the plasma
membrane to activate the MAPK protein kinase cascade is a
pivotal function of Grb2 in cells. It has been known for some time
that Grb2 could form dimers, however it has been debated as to
whether the dimeric state had any physiological relevance.
Here we used both in vitro and in vivo studies to show
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concentration-dependent Grb2 dimerization (Fig. 1 and
Supplementary Fig. 2). We have demonstrated that the
monomer–dimer population can be perturbed by Y160
phosphorylation and the binding of a ligand to the SH2
domain of Grb2 (Figs 2,3). We addressed the issue of whether
there is a functional consequence of disruption of the dimeric
state in cells and demonstrated that the regulation of the self-
association state of Grb2 is intimately related to the receptor
tyrosine kinase activity. The monomeric form is the signalling-
competent active form whereas dimeric Grb2 is the inactive
inhibitory form. Only monomeric Grb2 associates with SOS,
while both monomeric and dimeric form can engage a
phosphorylated tyrosine residue (Fig. 4b).
The change from dimeric–monomeric state in cells is strongly
inﬂuenced by upregulation of kinase activity and the resultant
phosphorylation of Grb2 itself or of cognate ligands. The
requirement of Grb2 to dissociate from the dimeric state provides
a further ‘check-point’ in MAPK signal transduction. Driving the
dissociation of Grb2 through increased kinase activity can be
reversed by phosphatases. We have previously reported that
the tyrosine phosphatase Shp2 is a speciﬁc phosphatase for
Grb2 (ref. 20).
Phosphorylation, however, is not the only mechanism for
dGrb2 dissociation. Protein expression levels will also impact on
this. This is reﬂected in downstream signalling, where over-
expression of wild-type Grb2 increases the population of dimer
and hence suppresses MAPK activation (Fig. 4a and
Supplementary Fig. 5). However, overexpression of Grb2 coupled
with Y160 phosphorylation leads to increased MAPK activation
(Supplementary Fig. 9). Thus, initiation of MAPK signalling is
modulated by several cellular conditions and ﬂuctuations in these
could have signiﬁcant impact on cellular outcome.
Human cancer tissue analysis shows a signiﬁcant increase in
Grb2 phosphorylation in high-grade pre-metastatic tumours,
further highlighting the importance of mGrb2 in signal
transduction and cancer progression. Therefore, the mechanistic
insight gained from this work might pave the way for developing
novel strategies towards cancer therapy, based on stabilizing the
formation of Grb2 dimers. One inventive way of achieving this
might be based on a small molecule which could irreversibly
crosslink the two monomers across the dimer interface. Together
these results from human cancer patients conﬁrm the importance
of mGrb2 in intracellular signalling and suggest that pY160 could
be used as a potential predictive biomarker in personalized cancer
therapy.
Methods
Reagents. Anti-Grb2 (C23), anti-FRS2 and anti-SOS antibodies were obtained
from Santa Cruz Biotechnology. Anti-phospho-Erk and anti-total Erk antibodies
were from Cell Signaling. All antibodies were diluted to 1:1,000. Anti-pY160
antibody was raised against QPT(pY)VQALFDFDPQC peptide (GenScript).
Phospho-EGFR peptide FLPVPE(pY)INQSVPKR, phospho-Shc peptide
EEPPDHQ(pY)YN-DFPGK and SOS1 peptide PVPPPVPPRRRPEY were
purchased from GenScript. The SomaPlex Protein Microarray of Human Breast
Tumor & Normal Tissue (PMA2-001-L), as well as the matching cell lysates were
purchased from Protein Biotechnologies. Multi-organ tissue microarray slides
(MUT951), colon cancer tissue array (COC1262) and prostate cancer tissue array
(PRC481) were purchased from Pantomics.
Molecular cloning. Gene fragments encoding Grb2 were cloned into pECFP-C1
(Clontech) in the BamHI site to create the CFP–Grb2 construct. The monomeric
RFP (mRFP) was cloned into the NheI/HindIII site of the pcDNA3.1(þ ) vector
(Invitrogen). Grb2 was then subcloned into the BamHI/EcoRI sites to create
the RFP–Grb2 construct. In both cases the ﬂuorescent tag was placed at the
N-terminus of Grb2. For histidine-tagged protein expression and puriﬁcation,
Grb2 was cloned into BamHI/EcoRI site of a modiﬁed pET28a vector containing
tobacco edge virus protease (TEV) cleavage site. The Y160E and N188/214D
mutations were introduced into Grb2 by site-directed mutagenesis. Bacterial pro-
tein expression and puriﬁcation were performed as described previously20,28,29.
Strep-tagged Grb2 was created by fusing a WSHPQFEK sequence at the
N-terminus of the full-length Grb2. The PCR ampliﬁed DNA fragment was
inserted into the HindIII/PmeI site of pcDNA6-myc/His C vector (Invitrogen).
Bacterial GFP–Grb2 and RFP–Grb2 were created by cloning NdeI–SacI–BamHI-
(GFP or RFP)–HindIII–EcoRI–XhoI fragments from pEGFP-N1 or mRFP-
pcDNA3.1, respectively, into the NdeI and XhoI site of a pET28a vector. The full-
length Grb2 was then subcloned into the HindII/XhoI sites. Molecular cloning
expression and puriﬁcation of FGFR2 cytoplasmic domain in bacteria is described
elsewhere12.
Cell culture. HEK293T cells obtained from the American Type Culture Collection
were maintained in Dulbecco’s modiﬁed Eagle’s high glucose medium (DMEM)
supplemented with 10% (vol/vol) fetal bovine serum (FBS) and 1% antibiotic/
antimycotic (Lonza) in a humidiﬁed incubator with 10% CO2 as described
previously30–32. Stable HEK293T cells overexpressing GFP-tagged FGFR2 were
produced as described previously30. Control and Grb2 knockdown cells were
produced as described previously20. Mammalian cell transfection was performed in
a six-well plate using Metafectin Pro (Biontx-USA) reagents according to the
manufacturer’s instructions. Cells were lysed in 50mM HEPES (pH 7.5), 1% (v/v)
Igepal-C630, 1mgml 1 bacitracin, 1mM EDTA, 10mM NaF, 1mM sodium
orthovanadate, 10% (v/v) glycerol, 50mM NaCl, 1mM PMSF and Protease
Inhibitor Cocktail Set III (Calbiochem).
Immunoblotting. Immunoblotting was performed using the indicated antibodies.
Blots were cropped such that at least one marker position was present. Uncropped
full scans are shown in Supplementary Fig. 10.
Protein expression and puriﬁcation. 6 Histidine-tagged constructs of FGFR2
and Grb2 were expressed and puriﬁed from E. coli as described in refs 28,32.
It should be noted that puriﬁed Grb2 is inherently unstable as a monomer and
can be affected by inter-molecular disulphide bond formation.
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Figure 4 | Dimeric Grb2 inhibits while monomeric Grb2 promotes MAP
kinase activity. (a) Stable HEK293T cells overexpressing FGFR2–GFP
(as control, C) and strep-tagged wild-type Grb2 or the dimerization-
defective Y160E mutant were stimulated with 50 ng/ml FGF2 or EGF for 15
and 5min, respectively. Cell-lysates were analysed for phospho-ERK
(pERK), total ERK and Grb2 expression levels using speciﬁc antibody and
Odyssey infra-red imaging. (b) HEK293T cells overexpressing FGFR2–GFP
with indicated strep-tagged Grb2 in serum were lysed and subjected to
strep-tactin afﬁnity puriﬁcation. The resulting co-precipitated complexes
along with input cell-lysates were analysed for SOS and FRS2 binding using
respective antibody. The immunoblot was also re-probed for Grb2 as a
loading control. The data presented are representative of three independent
experiments.
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Cell imaging and FLIM. Cells were co-transfected with ﬂuorescent protein-tagged
Grb2 and then grown on glass coverslips for 24 h before experimentation. As
controls, cells expressing CFP alone or CFP–WTGrb2 with RFP-alone were also
analysed. All experiments were carried out in the presence of serum unless
indicated. Cells were ﬁxed by addition of 4% (w/vol) paraformaldehyde, pH 8.0.
Cells were washed six or seven times with PBS, pH 8.0, and then mounted onto a
slide with mounting medium (0.1% p-phenylenediamine/75% glycerol in PBS at
pH 7.5–8.0). Cells were imaged using a Leica SP5 II confocal microscope with
internal PMT FLIM detector. CFP was excited at 860 nm with titanium–sapphire
pumped laser (Mai Tai BB, Spectral Physics) and SPC830 data and image
acquisition card for time-correlated single photon counting. Data processing and
analysis were done using B&H SPC FLIM analysis software. The ﬂuorescence
decays were ﬁt with a single exponential decay model. FLIM experiments were
performed as described previously20,28,29,33.
Single molecule FLIM. For Grb2 as FRET donor histidine-tagged Grb2 was
bacterially expressed and puriﬁed, labelled with Atto488 NHS ester according to
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Figure 5 | Analysis of human colon and prostate cancer tissues for Y160 phosphorylation. Using the pY160 antibody IHC was performed on
multi-tumours tissue microarray of 95 samples with 40 types of tumours from 27 organs. (a) Weak or no staining for Grb2 Y160 phosphorylation in
grade I colon adenocarcinoma. (b) Strong staining for Grb2 Y160 phosphorylation in grade III colon adenocarcinoma. (c) Weak or no staining for Grb2
Y160 phosphorylation in grade II prostate adenocarcinoma. (d) Moderate staining for Grb2 Y160 phosphorylation in grade III prostate adenocarcinoma.
A signiﬁcant increase in the level of pY160 phosphorylation is seen in higher-grade tumour samples. The bars on a–d correspond to 50mm. (e) The
pY160 antibody staining patterns for 118 colon cancer tissue samples. The samples were scored according to the pY160 staining as weak or none,
moderate and strong and plotted against tumour grade as percentage. Data compiled from normal tissues (n¼42), and tumours grade I (n¼ 28),
grade II (n¼ 34) and grade III (n¼ 14) which shows a progressive increase in the strength of pY160 staining with higher tumour grade. (f) The
pY160 antibody staining patterns for 42 clinical prostate cancer tissue samples with the relative staining patterns for pY160 antibody. As above,
samples were scored, sorted and plotted against tumour grade as percentage. Normal and/or hyperplasic tissue (n¼ 15), tumour grade II (n¼ 13)
and grade III (n¼ 14). Here the pY160 staining is only associated with malignant tumours and intensity of staining is increased in tumours with a
higher level of malignancy.
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the manufacturers’ instructions. For Grb2 as FRET acceptor, histidine-tagged Grb2
was expressed and puriﬁed and the tag was removed by TEV cleavage. Uncleaved
proteins and TEV were removed by subtractive gel ﬁltration. Puriﬁed Grb2 was
then labelled with Atto 550 NHS ester according to the manufacturer instructions.
In both cases free dyes were removed by size exclusion chromatography and
quantiﬁed. Only labelled proteins with 1:1 (protein:dye) ratio was used for
experiments.
Atto488–Grb2 was loaded onto Talon beads and placed on a 35-mm glass-
bottom dish (MatTek Corporation) containing 250 ml PBS pH 7.5. Beads were
allowed to settle and then the reference lifetime of the Atto488–Grb2 in the absence
of acceptor was measured. Without disturbing the beads a ﬁnal concentration
0.5 mM Atto550–Grb2 was then added and allowed to equilibrate and form dimers
for 30–60min. The lifetime was again measured and proceeded to the next
treatment. For each treatment extreme care was taken to avoid disturbing the
beads. For smFLIM with GFP-tagged Grb2, GFP–Grb2, was immobilized on
GFP-trap agarose beads (Chromotek).
Immunohistochemistry staining. All tissues utilized in this study were of human
origin and purchased from Pantomics Inc and employed in IHC experiments and
scoring according to research protocols approved by the IACUC of The University of
Texas MD Anderson Cancer Center (Houston, TX). Slides were baked at 60 C for
30 min and then the temperature was increased to 72 C. Slides were then rinsed
three times with Bond Dewax followed by absolute alcohol and Bond Wash. The
temperature was then increased to 100 C, and Bond ER Solution 1 (pH6) was
applied and incubated for 30min. Slides were rinsed with Bond Wash and the
temperature was allowed to come down to room temperature. Anti-phospho-pY160
antibody was applied at 1:50 dilution (0.6mgml 1 ﬁnal) and incubated for 15min
at room temperature followed by rinsing with Bond Wash. Post Primary was applied
and incubated for 8min, then slides were again rinsed with Bond Wash. Bond
Polymer was applied and incubated for 8min followed by rinsing with Bond Wash
two times and then with distilled water. Peroxide Block was applied and incubated
for 5min, then rinsed with Bond Wash four times and then washed with distilled
water. 3,30-Diaminobenzidine (DAB) was applied and incubated for 10min then
rinsed with distilled water three times. Haematoxylin was applied and incubated for
7min, then rinsed with Bond Wash. Slides were then removed from Leica Bond III
and rinsed with distilled water four times. They were then dehydrated in graded
alcohols and xylene, then coverslipped with ClearMount from American MasterTech
using Leica CV5030 coverslipper. Preparation of IHC slides for cultured cells,
5 150mm dishes were used per block. Cells were scraped from dishes with a
rubber policeman and pelleted by centrifugation at 800 rpm for 5min. The cell pellet
was ﬁxed overnight with 10% formalin and then changed to 70% ethanol before
embedding into formalin ﬁxed parafﬁn embedded (FFPE) blocks.
Microscale thermophoresis. The MST method has been described in detail
elsewhere34. The KD, dimer for Grb2 dimers was measured using the Monolith
NT.115 from Nanotemper Technologies. Proteins were ﬂuorescently labelled with
Atto488 according to the manufacturer’s protocol. Labelling efﬁciency was determined
to be 1:1 (protein to dye) by measuring the absorbance at 280 and 488nm. A solution
of unlabelled Grb2 was serially diluted from about 30mM to 7.3nM in the presence of
100nM labelled Grb2. The samples were loaded into silica capillaries (Polymicro
Technologies) after incubation at room temperature for 15min. Measurements were
performed at 20 C in PBS without calcium and magnesium (Lonza) containing
0.01% Tween 20, by using 20% LED power and 40% IR-laser power. Measurements
were also carried out on 40 and 60% IR-Laser power for comparison. Data analyses
were performed using Nanotemper Analysis software, v.1.2.101.
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